Deutsche Bank’s Aldeyra Therapeutics ALDX Stock Holding History

Deutsche Bank’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200	Closed	-$1K	–	5265
2019 Q1	$1K	Buy	+200	New	+$1.7K	﹤0.01%	5100

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Deutsche Bank's ALDX Position: Q2 2026 in Review

Deutsche Bank sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 50,271 shares — an estimated $85K sold.

Deutsche Bank first reported a position in ALDX in Q2 2014 and held it in 38 quarters. The position peaked at $3.56M in Q1 2021. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Deutsche Bank reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
Deutsche Bank sold 50,271 Aldeyra Therapeutics shares in Q2 2026, an estimated $85K.
Deutsche Bank first reported a position in Aldeyra Therapeutics in Q2 2014 and held it in 38 quarters.
Deutsche Bank's Aldeyra Therapeutics position peaked at $3.56M in Q1 2021.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.